Qilu Pharmaceutical invests heavily in an innovative microsphere product

Recently, Qilu Pharmaceutical and InnoBM Pharmaceuticals have reached an agreement to jointly advance the development of BM601, a metallic embolization microsphere product for TACE treatment of liver cancer. Under the terms of the agreement, Biomay Biotech will receive milestone payments totaling over RMB 200 million, along with additional sales royalties and overseas revenue sharing.

BM601 is a Class III medical device independently developed by InnoBM Pharmaceuticals based on the original technology of Professor Liu Zhuang’s team at Suzhou University. It holds independent intellectual property rights, and its unique mechanism of action can significantly enhance the therapeutic efficacy of transarterial chemoembolization (TACE).

In early clinical studies targeting patients with unresectable primary liver cancer, BM601 demonstrated notable clinical advantages, showing promise to provide more effective treatment options for patients with intermediate to advanced liver cancer.

Source: DXY Insight Database